Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

By H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H. Diener, W. Hacke, J. Oldgren, P. Sinnaeve, A. Camm, Paulus Kirchhof. Europace, 2015

1,229 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/6e1d38b3c906eede0c72cc376a354d35e11f070b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

[2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, methodology): “Despite the absence of data from clinical trials, NOACs can be used in patients who have atrial fibrillation associated with a bioprosthesis after the third postoperative month.(43) There is no evidence to support the use of antiplatelet agents beyond 3 months in patients with surgical bioprostheses”
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, methodology): “‘truly uninterrupted’) or to go for a short cessation period (last NOAC dose on the day before the procedure), depends on a number of factors including renal function, CHA2DS2-VASc score, experience of the operator, and routine practice of heparin administration prior to (first) trans-septal punctur”
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “Kidney function should be regularly monitored in AF patients on OACs to allow dose adaptation for those on NOACs (Table 14) and to refine risk estimation.(416)”
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “tral stenosis, only oral vitamin K antagonists should be used for prevention of thromboembolic stroke.(370) The dabigatran dose should be reduced to 110 mg b.”
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report (2012, background): “In case of urgent surgery, reversal of anticoagulation or specific measures may be required.(205,466)”